Kutaner Lupus erythematodes ausgelöst durch Tislelizumab

JDDG: Journal der Deutschen Dermatologischen GesellschaftEarly View CLINICAL LETTER Kutaner Lupus erythematodes ausgelöst durch Tislelizumab Cutaneous lupus erythematosus induced by tislelizumab Weiquan Chen, Weiquan Chen orcid.org/0000-0002-2465-8697 Institute of Dermatology and Venereal diseases, Department of Dermatology and Venereal diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, ChinaSearch for more papers by this authorXuan Song, Xuan Song Institute of Dermatology and Venereal diseases, Department of Dermatology and Venereal diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, ChinaSearch for more papers by this authorYing Zhou, Corresponding Author Ying Zhou [email protected] Institute of Dermatology and Venereal diseases, Department of Dermatology and Venereal diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China Korrespondenzanschrift Ying Zhou, MD,PhD, NO.57 Ren min da dao Road Nan, Xiashan District, Zhanjiang, Guangdong Province, 524001 China. Email: [email protected]Search for more papers by this author Weiquan Chen, Weiquan Chen orcid.org/0000-0002-2465-8697 Institute of Dermatology and Venereal diseases, Department of Dermatology and Venereal diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, ChinaSearch for more papers by this authorXuan Song, Xuan Song Institute of Dermatology and Venereal diseases, Department of Dermatology and Venereal diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, ChinaSearch for more papers by this authorYing Zhou, Corresponding Author Ying Zhou [email protected] Institute of Dermatology and Venereal diseases, Department of Dermatology and Venereal diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China Korrespondenzanschrift Ying Zhou, MD,PhD, NO.57 Ren min da dao Road Nan, Xiashan District, Zhanjiang, Guangdong Province, 524001 China. Email: [email protected]Search for more papers by this author First published: 25 April 2024 https://doi.org/10.1111/ddg.15396_gRead the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. LITERATUR 1Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update. J Clin Oncol. 2021; 39(36): 4073-4126. 10.1200/JCO.21.01440 CASPubMedWeb of Science®Google Scholar 2Ma B, Anandasabapathy N. Immune checkpoint blockade and skin toxicity pathogenesis. J Invest Dermatol. 2022; 142(3 Pt B): 951-959. 10.1016/j.jid.2021.06.040 CASPubMedWeb of Science®Google Scholar 3Shen L, Kato K, Kim SB, et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): A randomized phase III study. J Clin Oncol. 2022; 40(26): 3065-3076. 10.1200/JCO.21.01926 CASPubMedWeb of Science®Google Scholar 4Bhardwaj M, Chiu MN, Pilkhwal Sah S. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance. Cutan Ocul Toxicol. 2022; 41(1): 73-90. 10.1080/15569527.2022.2034842 CASPubMedWeb of Science®Google Scholar 5Shao K, McGettigan S, Elenitsas R, et al. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy. J Cutan Pathol. 2018; 45(1): 74-77. 10.1111/cup.13059 PubMedWeb of Science®Google Scholar 6Fetter T, Braegelmann C, de Vos L, Wenzel J. Current concepts on pathogenic mechanisms and histopathology in cutaneous lupus erythematosus. Front Med (Lausanne). 2022; 9:915828. 10.3389/fmed.2022.915828 PubMedWeb of Science®Google Scholar 7Curran CS, Gupta S, Sanz I, Sharon E. PD-1 immunobiology in systemic lupus erythematosus. J Autoimmun. 2019; 97: 1-9. 10.1016/j.jaut.2018.10.025 CASPubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation